Endoscopic Hemostasis Devices Market By Product Type (Mechanical Devices, Thermal Devices, Injection Devices, Topical Hemostatic Agents), By Application (Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, Non-variceal Bleeding, Variceal Bleeding, Others), By End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Endoscopic Hemostasis Devices Market in the coming years?

The Endoscopic Hemostasis Devices Market accounted for USD 2.87 Billion in 2024 and USD 2.99 Billion in 2025 is expected to reach USD 4.47 Billion by 2035, growing at a CAGR of around 4.1% between 2025 and 2035. The endoscopic hemostasis devices market is focused on medical equipment that is involved in the regulation during endoscopic procedures. They play a very significant role in gastrointestinal (GI) cases where bleeding has to be controlled before complications arise, and the devices have to be applied correctly and in an efficient manner. Devices such as hemostasis assist in checking blood loss through a variety of actions such as mechanical clipping, thermal coagulation, and injection therapy.

They are of particular importance in examinations like a polypectomy, biopsy, or the management of bleeding ulcers and varices. The types include hemostatic products produced in the market, including hemostatic clips, thermal probes, sprays, rays, as well as injection needles. The rising trend of GI disorders, aging populations, and the utilization of minimally invasive surgeries are forcing demand because of this. Increases in endoscopic technologies also lead to improvements in accuracy and effectiveness in the control of bleeding. The primary users of these devices include hospitals, specialty clinics, and ambulatory surgical centers. With the entire world focusing on the diagnosis and treatment of gastrointestinal disorders at an early stage, the market is experiencing healthy growth in both developed and emerging nations. 

What do industry experts say about the Endoscopic Hemostasis Devices Market trends?

“Novel haemostatic powders and advanced clipping systems have transformed endoscopic management of upper GI bleeding, significantly reducing rebleeding rates and improving patient outcomes.”

• Dr. Alan N. Barkun, Canadian gastroenterologist and Director of Digestive Endoscopy at McGill University Health Centre

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Endoscopic Hemostasis Devices Market?

Is the rising incidence of gastrointestinal bleeding due to aging populations and chronic NSAID use driving market growth?

The Endoscopic Hemostasis Devices Market is being propelled by the increasing rates of gastrointestinal (GI) bleeding, especially in elderly patients, as well as patients using chronic nonsteroidal anti-inflammatory drugs (NSAIDs). According to the U.S. National Library of Medicine, UGI bleeding causes about 75 percent of acute GI bleed cases and about 40 percent of the GI-related hospital admissions. They may be caused by peptic ulcers, oesophageal varices, and gastritis, which are commonly connected to the prolonged use of NSAIDs and healthcare problems in old age. With the incidence of upper GI bleeding being 80 to 150 per 100,000 persons per year, the prevalence of in-hospital mortality going as high as 10% the significance of timely interventions is of high priority.

Endoscopic hemostasis devices offer a minimally invasive solution to the issue of controlling such bleeding, making it possible to rapidly control such bleeding by creating the ability to proceed through the issue rapidly without the need for an open surgery. Their growing implementation in ambulatory surgical centers and hospitals is an indicator of their quality and success in clinical activities. The instruments enable patients to use less time in the hospital and lessen the complications and recuperation interval. With the current state of a burgeoning aging global population and the strong trend of increasing GI-related disorders, demand will remain high, promoting the ever-growing need for these high-performance hemostasis assisting products, which are already seen as invaluable in the practice of great gastroenterology today.

Is increasing preference for minimally invasive procedures boosting demand for endoscopic hemostasis devices?

The rising trend towards the use of minimally invasive procedures is having a tremendous positive impact on making the Endoscopic Hemostasis Devices Market grow. Among the most significant advantages of these procedures, we can note quicker recovery, lower risks of complications, and shorter hospitalization, which is why they are becoming more popular among patients and medical workers. Endoscopic methods of hemostasis have enabled patterns of bleeding to be controlled precisely, avoiding open surgery, which is in tandem with the reduced invasiveness of treatment patterns being observed throughout the globe. Consequently, healthcare organizations are fast integrating these devices into the everyday GI processes in order to enhance clinical effectiveness and performance.

The U.S. Agency for Healthcare Research and Quality (AHRQ) provides statistics according to which the number of outpatient gastrointestinal endoscopies proportionally rose over the years, leaving no doubt that the tendency is toward minimally invasive diagnostics and treatments. The trend augers well with the development of the Endoscopic Hemostasis Devices Market because there are increasing procedures that need to be administered with efficient instruments to control bleeding. As the awareness increases, together with the access to higher medical technologies, the market is anticipated to further grow accordingly with this shift in procedure.

Are the high costs of advanced hemostasis devices limiting adoption in price-sensitive markets?

The increased price of high-tech hemostasis devices acts as a major inhibitor to the Endoscopic Hemostasis Devices Market, especially in price-sensitive and emerging markets. Their prices are high because such devices usually involve the use of special materials, high accuracy in engineering, and the ability to comply with state-of-the-art endoscope systems. Inexpensive budgets and weak reimbursement mechanisms in the low- and middle-income nations make it difficult to spend on these technologies by hospitals and clinics.

Consequently, most medical professionals in these areas lack sophisticated or modern hemostasis instruments that are important in therapy.  Moreover, the initial expense of equipment and the need for continuous maintenance and training also reduce the chances of mass implementation. This is a financial obstacle that limits the market expansion capacity in the emerging economies, even though there is an increasing demand for the management of GI bleeding. Such a gap will be narrowed down with cost-efficient innovations and specific pricing policies to ensure that fancy devices are affordable in any part of the world.

Can expansion into emerging markets with improving healthcare infrastructure unlock new growth avenues?

The Endoscopic Hemostasis Devices Market has enormous prospects in expanding into emerging markets, with better healthcare infrastructure. The investments being made by many countries in Asia Pacific, Latin America, and the Middle East are on a large scale in upgrading their system; this involves the creation of endoscopy units as well as surgical centers. Demand for efficient tools of hemostasis is likely to increase as more people have access to diagnostics and minimally invasive procedures.

There is also a huge number of patients with increasing encounters of gastrointestinal disorders in emerging markets, which also propels the demand for endoscopic procedures. Besides, there is increasing medical tourism, currently evident in India, Thailand, and Mexico, which is generating further demand for more sophisticated medical technologies. Companies that provide cost-efficient, convenient-to-use, and flexible devices will have a good advantage to gain momentum in these areas. By means of strategic affiliations and localization, the companies will be able to have a quick and increasing customer base and unleash the long-term growth prospects as well.

Will the development of user-friendly, disposable, and portable devices enhance product accessibility?

The innovative expertise of disposable and friendly devices with portability involves a high chance of expanding in the Endoscopic Hemostasis Devices Market. The operation of conventional tools of hemostasis usually requires the expertise of an operator, sterilization, and periodic servicing procedures that restrain their application in small hospitals or low-resource facilities. Conversely, single-use and easily disposable devices minimize nurses and reduce the danger of cross-contamination, becoming a suitable option in large or isolated medical units.

The portable aspect also extends the market area since it can facilitate emergency and outpatient treatment in outpatient or ambulatory facilities. Such innovations may increase the procedural efficacy and broaden accessibility, even in regions with poor infrastructure. Such products have the potential to attract both the developed and developing markets by overcoming usability, safety, and cost issues. The move towards simplified and disposable hemostasis devices is a convenient and palpable opportunity, given that the demand for faster, safer, and more efficient hemostasis of GI bleeding management is increasing.

What are the key market segments in the Endoscopic Hemostasis Devices industry?

Based on the product type, the Endoscopic Hemostasis Devices Market has been classified into Mechanical Devices, Thermal Devices, Injection Devices, and Topical Hemostatic Agents. Mechanical Devices form the largest section of the Endoscopic Hemostasis Devices Market. The popularity of such devices is explained by their high efficiency in terms of effectiveness, reliability, and our ability to apply them during any endoscopic procedures to produce immediate bleeding control. The utilization of such products as endoscopic clips and band ligators in the case of upper and lower gastrointestinal bleeding is so widely spread that they are indispensable tools. Their non-invasive character also decreases the number of complications and improves patient outcomes, which also promotes their extensive implementation in surgeries and medical institutions.

Easy to use and more precise, rotate and repositionable clips are the result of advancements in the design of the clips and have helped them take over. Use of mechanical devices also reduced the risk of tissue damage associated with the use of thermal methods, which is a very essential aspect when conducting delicate GI procedures. The rising GI bleeding condition associated with the demand for universal availability of rapid and effective treatment methods has contributed immensely towards the rising demand for mechanical hemostasis tools in the developed as well as in the emerging markets.

Based on the application, the Endoscopic Hemostasis Devices Market has been classified into Mechanical Devices, Thermal Devices, Injection Devices, and Topical Hemostatic Agents. The most dominant segment in the Market is the Upper Gastrointestinal Bleeding. Mostly, this dominance has been because of the high prevalence of diseases such as peptic ulcers, esophageal varices, and gastric erosions, which are some of the main causes of upper GI tract bleeding. The conditions usually necessitate an immediate endoscopic procedure to avert serious effects, and thus, hemostatic devices are important. The endoscopic procedure on upper GI bleeding is more frequently conducted compared to lower GI bleeding, leading to increased consumption of hemostasis devices in the segment.

The segment is also boosted by the presence of high-endoscopic technologies and the availability of more diagnostic awareness. When it comes to emergent healthcare facilities, the necessity to provide patients with timely hemostasis in the upper gastrointestinal (GI) tract and stabilize the patient spills over into the need to use mechanical, thermal, and injection solutions. With the rising population of the aged communities and the use of NSAIDs worldwide, the cases of upper GI bleeding are still on the high side, and this reality solidifies the market dominance of the segment.

Which regions are leading the Endoscopic Hemostasis Devices Market, and why?

The North American Endoscopic Hemostasis Devices Market regional environment is an advanced market, mainly due to the high availability of healthcare facilities and the high incidence of gastrointestinal disease. The United States has a dominant market share in the region because of high adoption rates of minimally invasive procedures and the existence of leading players, including Boston Scientific and Cook Medical. The market is growing due to the raised concern on early diagnosis of the GI disease and the boost in endoscopic procedures undertaken annually.

The presence of government efforts to control healthcare expenditures and enhance surgical outcomes has also led to the adoption of effective hemostasis technologies in hospitals and ambulatory surgical centers. Also, they are increasing in the U.S. and Canada, with good reimbursement policies. There is also the continuous conduct of clinical research and premature regulatory approvals in the area, which facilitates a quicker introduction of products. North America is likely to continue dominating this market with the current aging demographics as well as increasing expenditure on healthcare.

The Asia Pacific Endoscopic Hemostasis Devices Market is showing rapid growth powered by the growing healthcare investments in the region, the rising awareness of people in the region regarding the importance of gastrointestinal health, and the growing accessibility of endoscopic procedures. Countries such as China, Japan, South Korea, and India are leading as a result of increased incidences of patients and the advancement of hospital facilities. Japan and its powerful endoscopy-related technology and endoscopy-related companies, such as Olympus and Fujifilm, are at the center of the region in terms of innovation.

The expanding incidence of GI-related diseases like ulcers and colorectal cancer is swelling the need for effective hemostasis devices in the region. Governments are assisting in the upgrading of healthcare; however, more areas of private hospitals are turning to high-tech, minimally invasive technology. Besides, the existence of local manufacturers, whose products are affordable, is increasing the regional competitiveness. In certain sections of Southeast Asia where the issue of medical tourism has been on the rise, there is an emergence of a need to use safe and efficient endoscopic treatments.  

What does the competitive landscape of the Endoscopic Hemostasis Devices Market look like?

The Endoscopic Hemostasis Devices Market competitive environment can be described as the presence of a number of global and regional market players with an orientation toward product expansion through the development of further innovations and strategic partners. The major players in the market include Olympus Corporation, Boston Scientific, and Cook Medical, which have an impressive variety of hemostatic clips, sprays, and coagulation instruments. These companies spend a lot of money on R&D so as to come up with advanced equipment where the precision will be good, as well as causing less discomfort to the patients.

Independent business enterprises and medium-sized firms that have started to provide cheap services are also becoming popular as they focus on niche solutions to improve. Joint ventures with surgical institutes and hospitals are equally aiding the firms to increase their geographic baseline, especially in new markets. Furthermore, the regulatory clearances and the FDA approvals are essential in developing the competitive principle. Depending on the increasing requirement of endoscopic management of gastrointestinal bleeding and the tendency to lower minimal invasive treatment, the competition has increased. Consequently, the players are attempting to increase the efficacy of devices, ergonomics of users, and their ease of integration into imaging technologies to acquire market share.

Endoscopic Hemostasis Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Endoscopic Hemostasis Devices industry?

• In May 2024, Galvanize Therapeutics, Inc., a biomedical platform company, received U.S. FDA 510(k) clearance for its INUMI Flex endoscopic needle, enabling its use with the Aliya PEF System for soft tissue ablation. This milestone expands treatment options by allowing minimally invasive endoscopic delivery, building on the capabilities of the previously approved percutaneous needle.

Report Coverage:

By Product Type

• Mechanical Devices
• Thermal Devices
• Injection Devices
• Topical Hemostatic Agents

By Application

• Upper Gastrointestinal Bleeding
• Lower Gastrointestinal Bleeding
• Non-variceal Bleeding
• Variceal Bleeding
• Others

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Olympus Corporation
• Boston Scientific Corporation
• Cook Medical
• ConMed Corporation
• Medtronic plc
• ERBE Elektromedizin GmbH
• STERIS plc
• Pentax Medical
• Fujifilm Holdings Corporation
• Smith & Nephew plc
• Karl Storz SE & Co. KG
• US Endoscopy
• Apollo Endosurgery
• Medico’s Hirata Inc.
• Ovesco Endoscopy AG

Frequently Asked Questions (FAQs)